KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $21.1 million.

  • Supernus Pharmaceuticals' Cash from Financing Activities rose 58513.82% to $21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 1218.39%. This contributed to the annual value of $12.2 million for FY2024, which is 10306.45% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Cash from Financing Activities of $21.1 million as of Q3 2025, which was up 58513.82% from $935000.0 recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Cash from Financing Activities peaked at $80.2 million during Q1 2023, and registered a low of -$478.9 million during Q2 2023.
  • Its 5-year average for Cash from Financing Activities is -$27.7 million, with a median of $1.7 million in 2024.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first surged by 692187.5% in 2021, then crashed by 2116977.56% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$136.7 million in 2021, then skyrocketed by 102.07% to $2.8 million in 2022, then plummeted by 61.4% to $1.1 million in 2023, then surged by 439.38% to $5.9 million in 2024, then skyrocketed by 257.69% to $21.1 million in 2025.
  • Its last three reported values are $21.1 million in Q3 2025, $935000.0 for Q2 2025, and -$21.4 million during Q1 2025.